Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria

ROCKVILLE, Maryland, June 29, 2011 /PRNewswire/ --

Sanaria's mission is to develop and commercialize whole-parasite malaria vaccines that confer high-level, long-lasting protection against malaria caused by Plasmodium falciparum and P. vivax. In the process of developing these vaccines, Sanaria has developed the capacity to manufacture and assay malaria parasites and mosquitoes in a highly regulated, cGMP compliant, industrial setting. These parasites, mosquitoes, and assay services are now available to the general research community as Sanaria Inc. announces the launch of its Sanaria ^®  Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology.

Sanaria ^®  Plasmodium falciparum Sporozoite Reagents :  Aseptic, purified, vialed, cryopreserved, attenuated and non-attenuated Plasmodium falciparum (Pf) sporozoites.

Sanaria ^®  PfSPZ Challenge Mosquitoes :  Live, aseptic and non-aseptic P. falciparum infected mosquitoes. These well-characterized mosquitoes are for experimentally challenging volunteers in studies assessing malaria vaccines and drugs and for laboratory-based research.

Sanaria ^®  Plasmodium Reagents :  Purified, vialed, cryopreserved, attenuated and non-attenuated Plasmodium species sporozoites, as well as other life cycle stages for laboratory-based research studies.  

Sanaria ^®  Plasmodium Reagent Slides : Slides for immunofluorescence assays to detect antibodies against purified sporozoite, and asexual erythrocytic, sexual erythrocytic and/or mosquito stages of Plasmodium species.

Sanaria ^®  Anopheles Reagents : Aseptic and non-aseptic Anopheles stephensi mosquitoes and derived material for laboratory-based research studies.

Sanaria ^®  Plasmodium Assay Services : Assessment of the effects of antibodies and drugs on the capacity of P. falciparum and P. vivax sporozoites to invade and develop in hepatocytes (inhibition of sporozoite invasion and inhibition of liver stage development assay), and of P. falciparum gametocytes to develop to oocysts and sporozoites in mosquitoes (transmission blocking assay). Assessment of antibodies to all life cycle stages of Plasmodium species by immunofluoresence assays and to selected antigens by ELISA.

Monoclonal Antibodies: Sporozoite, liver, and blood stage monoclonal antibodies.

Sanaria ^®  Custom Services: Sanaria will manufacture Plasmodium species reagents to meet your specifications.

For more information please visit http://www.sanaria.com. For pricing and other information please e-mail sales@sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Public Relations Contact: arichman@sanaria.com Investor Contact: rcthompson@sanaria.com

SOURCE Sanaria Inc.